SCHEMBL3811229

SCHEMBL3811229

CN(Cc1ccc(C(=O)N2CCCC3CCCC=C32)cc1)C(=O)c1cccc(C#N)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
CASR P41180 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
TACR1 P25103 1/20 0.39
CARM1 Q86X55 2/20 0.39
CCR1 P32246 1/20 0.38
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
PRMT8 Q9NR22 1/20 0.37
POLB P06746 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
ATM Q13315 1/20 0.36
ACACB O00763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3811382 0.86 KMT2A (0.43) KMT2AMEN1MAPTMAPK1
SCHEMBL3810932 0.86 HDAC1 (0.47) KMT2AMEN1
SCHEMBL3811232 0.79 CNR2 (0.45) NSD2KMT2AMEN1CASRMAPT
SCHEMBL3813361 0.79 NSD2 (0.49) NSD2KMT2AMEN1ACACB
SCHEMBL3815228 0.78 NSD2 (0.47) NSD2KMT2AMEN1MAPTMAPK1
SCHEMBL3809230 0.77 HRH3 (0.39) KMT2AMEN1
SCHEMBL3819937 0.76 AVPR2 (0.39) POLB
SCHEMBL3815269 0.75 NSD2 (0.45) NSD2KMT2AMEN1MAPTMAPK1
SCHEMBL3815532 0.75 NSD2 (0.47) NSD2KMT2AMEN1MAPTMAPK1
SCHEMBL3814572 0.74 NSD2 (0.42) NSD2KMT2AMEN1CASRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US claimed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP claimed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO claimed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD11B2, HSD3B1 NSD2 630/4885KMT2A 2957/4885MEN1 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.